$4.35
-4.2%Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Base year metrics used for projections
Forecast period and terminal assumptions
Calculation flow from present value to intrinsic value per share
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.2M | -$5.1M | -$2.5M | -$1.3M | -$636.4K | -$318.2K | -$159.1K | -$79.5K | -$39.8K | -$19.9K |
| Maintenance CapEx | -$50.0K | -$25.0K | -$12.5K | -$6.3K | -$3.1K | -$1.6K | -$781 | -$391 | -$195 | -$98 |
| Owner Earnings | -$10.2M | -$5.1M | -$2.6M | -$1.3M | -$639.5K | -$319.7K | -$159.9K | -$79.9K | -$40.0K | -$20.0K |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$9.5M | -$4.4M | -$2.0M | -$940.1K | -$435.2K | -$201.5K | -$93.3K | -$43.2K | -$20.0K | -$9.3K |
Continue your NTHI research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.